DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Auto-Diagnostic Biological therapy Angiotensin-converting enzyme inhibitors Immune-related adverse events Psoriasis Cardiotoxicity Bacterial rhinosinusitis Placebo Biologic drug Albinism Cancer Acute Myeloid Leukaemia AML Atopic dermatitis Bacterial Pregnancy Graft-versus-host disease Biologic therapy Adalimumab Drug survival Sacroiliitis Endocrine toxicity Amyloidosis Atrial fibrillation Infliximab Management Adolescent Autoimmune diseases Sipuleucel-T Burden Treatment Alitretinoin Epidemiology Antibiotics Ustekinumab COVID-19 Anxiété Access to care Arrhythmia Antimicrobials Méta-Analyse Intensive care Antimicrobial resistance Antimicrobial Stewardship Anti-HCV Direct Acting Antivirals DAA Spondylitis Alcohol Azathioprine Prostate cancer ASDAS Angiotensin receptor blockers Etanercept Adverse side effects Dermatology Pharmacovigilance Aging Pharmacoepidemiology Apre-milast Anti-TNF Quality of life Biologic Anti-Bacterial Agents Biosimilar Pharmaceuticals Arthritis Biological Therapy Primary adrenal insufficiency Accelerometer Addiction Antimicrobiens Beta-lactam antibiotics Anticancer drugs Anxiety Biologics Immune checkpoint inhibitors Ankylosing Vigibase® Immunotherapy Stability Antibiotic misuse Cardio-oncology Ankylosing spondylitis Pharmaco-Épidémiologie Glucocorticoids Systematic review Biomarkers Autoimmunity Apremilast Meta-Analysis BTK protein Biomédicaments Auto-immune hepatitis Cardiomyopathy Ethics ArtThese Antibiotic resistance Psoriatic arthritis Network meta-analysis Drug reaction Abus d'antibiotiques Axial spondyloarthritis Spondyloarthritis

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS